BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 10623733)

  • 1. Histone acetylation and reactivation of Epstein-Barr virus from latency.
    Jenkins PJ; Binné UK; Farrell PJ
    J Virol; 2000 Jan; 74(2):710-20. PubMed ID: 10623733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A role for the nucleosome assembly proteins TAF-Iβ and NAP1 in the activation of BZLF1 expression and Epstein-Barr virus reactivation.
    Mansouri S; Wang S; Frappier L
    PLoS One; 2013; 8(5):e63802. PubMed ID: 23691099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a novel element involved in regulation of the lytic switch BZLF1 gene promoter of Epstein-Barr virus.
    Kraus RJ; Mirocha SJ; Stephany HM; Puchalski JR; Mertz JE
    J Virol; 2001 Jan; 75(2):867-77. PubMed ID: 11134300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic histone modification of Epstein-Barr virus BZLF1 promoter during latency and reactivation in Raji cells.
    Murata T; Kondo Y; Sugimoto A; Kawashima D; Saito S; Isomura H; Kanda T; Tsurumi T
    J Virol; 2012 May; 86(9):4752-61. PubMed ID: 22357272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus (EBV) EB1/Zta protein provided in trans and competent for the activation of productive cycle genes does not activate the BZLF1 gene in the EBV genome.
    Le Roux F; Sergeant A; Corbo L
    J Gen Virol; 1996 Mar; 77 ( Pt 3)():501-9. PubMed ID: 8601788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein kinase C-independent activation of the Epstein-Barr virus lytic cycle.
    Gradoville L; Kwa D; El-Guindy A; Miller G
    J Virol; 2002 Jun; 76(11):5612-26. PubMed ID: 11991990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Negatively cis-acting elements in the distal part of the promoter of Epstein-Barr virus trans-activator gene BZLF1.
    Schwarzmann F; Prang N; Reichelt B; Rinkes B; Haist S; Marschall M; Wolf H
    J Gen Virol; 1994 Aug; 75 ( Pt 8)():1999-2006. PubMed ID: 8046403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the BRLF1 promoter and lytic cycle of Epstein-Barr virus by histone acetylation.
    Chang LK; Liu ST
    Nucleic Acids Res; 2000 Oct; 28(20):3918-25. PubMed ID: 11024171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARP1 restricts Epstein Barr Virus lytic reactivation by binding the BZLF1 promoter.
    Lupey-Green LN; Moquin SA; Martin KA; McDevitt SM; Hulse M; Caruso LB; Pomerantz RT; Miranda JL; Tempera I
    Virology; 2017 Jul; 507():220-230. PubMed ID: 28456021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promoter sequences required for reactivation of Epstein-Barr virus from latency.
    Binné UK; Amon W; Farrell PJ
    J Virol; 2002 Oct; 76(20):10282-9. PubMed ID: 12239304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EBV-immortalized isogenic human B-cell clones exhibit differences in DNA-protein complex formation on the BZLF1 and BRLF1 promoter regions among latent, lytic and TPA-activated cell lines.
    Cen H; McKnight JL
    Virus Res; 1994 Jan; 31(1):89-107. PubMed ID: 8165871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathways of activation of the Epstein-Barr virus productive cycle.
    Sinclair AJ; Brimmell M; Shanahan F; Farrell PJ
    J Virol; 1991 May; 65(5):2237-44. PubMed ID: 1850009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactivation of Epstein-Barr virus: regulation and function of the BZLF1 gene.
    Speck SH; Chatila T; Flemington E
    Trends Microbiol; 1997 Oct; 5(10):399-405. PubMed ID: 9351176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone hyperacetylation occurs on promoters of lytic cycle regulatory genes in Epstein-Barr virus-infected cell lines which are refractory to disruption of latency by histone deacetylase inhibitors.
    Countryman JK; Gradoville L; Miller G
    J Virol; 2008 May; 82(10):4706-19. PubMed ID: 18337569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BZLF1 interacts with chromatin remodelers promoting escape from latent infections with EBV.
    Schaeffner M; Mrozek-Gorska P; Buschle A; Woellmer A; Tagawa T; Cernilogar FM; Schotta G; Krietenstein N; Lieleg C; Korber P; Hammerschmidt W
    Life Sci Alliance; 2019 Apr; 2(2):. PubMed ID: 30926617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA miR-BART20-5p stabilizes Epstein-Barr virus latency by directly targeting BZLF1 and BRLF1.
    Jung YJ; Choi H; Kim H; Lee SK
    J Virol; 2014 Aug; 88(16):9027-37. PubMed ID: 24899173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the BZLF1 promoter of Epstein-Barr virus: identification of an anti-immunoglobulin response sequence.
    Shimizu N; Takada K
    J Virol; 1993 Jun; 67(6):3240-5. PubMed ID: 8388498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactivation of Epstein-Barr Virus by HIF-1α Requires p53.
    Kraus RJ; Cordes BA; Sathiamoorthi S; Patel P; Yuan X; Iempridee T; Yu X; Lee DL; Lambert PF; Mertz JE
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32641480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The B-cell specific transcription factor, Oct-2, promotes Epstein-Barr virus latency by inhibiting the viral immediate-early protein, BZLF1.
    Robinson AR; Kwek SS; Kenney SC
    PLoS Pathog; 2012 Feb; 8(2):e1002516. PubMed ID: 22346751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The chemopreventive compound curcumin is an efficient inhibitor of Epstein-Barr virus BZLF1 transcription in Raji DR-LUC cells.
    Hergenhahn M; Soto U; Weninger A; Polack A; Hsu CH; Cheng AL; Rösl F
    Mol Carcinog; 2002 Mar; 33(3):137-45. PubMed ID: 11870879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.